[go: up one dir, main page]

MX2022002667A - Composicion oftalmica para el tratamiento de uveitis. - Google Patents

Composicion oftalmica para el tratamiento de uveitis.

Info

Publication number
MX2022002667A
MX2022002667A MX2022002667A MX2022002667A MX2022002667A MX 2022002667 A MX2022002667 A MX 2022002667A MX 2022002667 A MX2022002667 A MX 2022002667A MX 2022002667 A MX2022002667 A MX 2022002667A MX 2022002667 A MX2022002667 A MX 2022002667A
Authority
MX
Mexico
Prior art keywords
uveitis
treatment
ophthalmic composition
pharmaceutical compositions
provides pharmaceutical
Prior art date
Application number
MX2022002667A
Other languages
English (en)
Inventor
Frank LÖSCHER
Markus Beier
Jörg Haisser
Chiara Silvana Leo
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2022002667A publication Critical patent/MX2022002667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona composiciones farmacéuticas que comprenden ciclosporina disuelta en un alcano semifluorado para usarse en el tratamiento de uveítis.
MX2022002667A 2019-09-06 2020-09-05 Composicion oftalmica para el tratamiento de uveitis. MX2022002667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19195793 2019-09-06
PCT/EP2020/074884 WO2021044045A1 (en) 2019-09-06 2020-09-05 Ophthalmic composition for the treatment of uveitis

Publications (1)

Publication Number Publication Date
MX2022002667A true MX2022002667A (es) 2022-04-07

Family

ID=67956455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002667A MX2022002667A (es) 2019-09-06 2020-09-05 Composicion oftalmica para el tratamiento de uveitis.

Country Status (10)

Country Link
US (1) US12419933B2 (es)
EP (1) EP4025235A1 (es)
JP (1) JP2022546980A (es)
KR (1) KR20220058577A (es)
CN (1) CN114449999A (es)
AU (1) AU2020340561B2 (es)
BR (1) BR112022004677A2 (es)
CA (1) CA3149046A1 (es)
MX (1) MX2022002667A (es)
WO (1) WO2021044045A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
BR112019012791A2 (pt) 2016-12-23 2019-12-03 Novaliq Gmbh composição oftálmica para o tratamento da doença do olho seco
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
MX2022002667A (es) 2019-09-06 2022-04-07 Novaliq Gmbh Composicion oftalmica para el tratamiento de uveitis.
WO2024015550A1 (en) * 2022-07-15 2024-01-18 Medpharm Iowa, Llc Process for preparing cannabis sugar wax concentrate and related compositions and methods
CN120916776A (zh) * 2023-02-13 2025-11-07 诺瓦利克有限责任公司 用于眼表疾病患者的眼部手术准备的眼用组合物

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
BE1003578A4 (fr) * 1988-10-26 1992-04-28 Sandoz Sa Nouvelles compositions ophtalmiques a base d'une cyclosporine.
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
IL141095A0 (en) 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
AU2004293027A1 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
WO2007008666A2 (en) 2005-07-08 2007-01-18 Ocularis Pharma, Inc. Compositions and methods for improving vision using adherent thin films
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
EP2070518A2 (en) 2006-07-25 2009-06-17 Osmotica Corp. Ophthalmic solutions
US9000048B2 (en) 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
ITMI20070890A1 (it) 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
EP2178502A2 (en) 2007-06-21 2010-04-28 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
JP5886523B2 (ja) 2008-01-09 2016-03-16 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の炎症性障害を処置するための治療組成物
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej
WO2010064636A1 (ja) 2008-12-02 2010-06-10 ロート製薬株式会社 眼科用組成物
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US20100279951A1 (en) 2009-05-01 2010-11-04 Aileen Morgan Method of treating allergic conjunctivitis with cyclosporin compositions
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CA2819988C (en) 2011-01-04 2019-11-12 Novaliq Gmbh O/w-emulsions comprising semifluorinated alkanes
EP3192501B1 (en) 2011-05-25 2020-05-13 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
WO2012160180A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Pharmaceutical composition for administration to nails
WO2013110621A1 (en) 2012-01-23 2013-08-01 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
EP2869819A4 (en) 2012-07-09 2016-03-09 Holden Brien Vision Inst COMPOSITIONS, METHODS AND / OR DEVICES FOR THE PREVENTION AND / OR TREATMENT OF OCULAR DROUGHT DISORDERS
JP6039152B2 (ja) 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
BR112015004997B1 (pt) 2012-09-12 2022-09-13 Novaliq Gmbh Composições oftálmicas contendo misturas de alcanos semifluorados
TR201812013T4 (tr) 2012-09-12 2018-09-21 Novaliq Gmbh Göz yikama bi̇leşi̇mleri̇.
EP2730291A1 (en) 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
TR201901462T4 (tr) 2013-03-14 2019-02-21 Panoptica Inc Gözün posterior segmentine ilaç uygulanması için oküler formülasyonlar.
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
UA124698C2 (uk) 2014-10-20 2021-11-03 Сентіс Фарма Прайвет Лімітед Офтальмологічний розчин
WO2016082644A1 (en) 2014-11-26 2016-06-02 The University Of Hong Kong A semifluorinated alkane based cleaner for removing emulsified droplets in the eye to reduce the complications associated with the emulsification of silicone oil
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2017055453A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
US10286035B2 (en) 2015-10-14 2019-05-14 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
CN109414431A (zh) 2016-06-01 2019-03-01 哈罗德·理查德·赫尔斯特伦 用副交感神经剂和抗交感神经剂治疗干眼病
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
EP3515420B1 (en) 2016-09-22 2023-11-08 Novaliq GmbH Pharmaceutical compositions for use in the therapy of blepharitis
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP3698785A1 (en) 2016-09-28 2020-08-26 Novaliq GmbH Compositions comprising a cannabinoid receptor binding ligand
BR112019012568A2 (pt) * 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
BR112019012791A2 (pt) 2016-12-23 2019-12-03 Novaliq Gmbh composição oftálmica para o tratamento da doença do olho seco
CN110678207B (zh) 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
EP3618782B1 (en) 2017-05-06 2021-05-26 Novaliq GmbH Drop dispenser
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
EP3687496A1 (en) 2017-09-27 2020-08-05 Novaliq GmbH Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
MX2020010078A (es) 2018-03-28 2021-02-26 Novaliq Gmbh Composicion farmaceutica que comprenden timolol.
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
KR20210080388A (ko) 2018-09-22 2021-06-30 노바리크 게엠베하 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020109192A1 (en) 2018-11-27 2020-06-04 Novaliq Gmbh Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
US20220226426A1 (en) 2019-05-24 2022-07-21 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
CN114206344A (zh) 2019-08-09 2022-03-18 诺瓦利克有限责任公司 包含前列腺素类似物的局部组合物
MX2022002667A (es) 2019-09-06 2022-04-07 Novaliq Gmbh Composicion oftalmica para el tratamiento de uveitis.

Also Published As

Publication number Publication date
EP4025235A1 (en) 2022-07-13
CA3149046A1 (en) 2021-03-11
KR20220058577A (ko) 2022-05-09
US12419933B2 (en) 2025-09-23
JP2022546980A (ja) 2022-11-10
US20230181679A1 (en) 2023-06-15
AU2020340561B2 (en) 2026-01-22
CN114449999A (zh) 2022-05-06
WO2021044045A1 (en) 2021-03-11
AU2020340561A1 (en) 2022-03-31
BR112022004677A2 (pt) 2022-05-17

Similar Documents

Publication Publication Date Title
MX2022002667A (es) Composicion oftalmica para el tratamiento de uveitis.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2020011868A (es) Inhibidores de los receptores erbb.
MX2021009673A (es) Moduladores de ror-gamma.
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
BR112019007806A2 (pt) composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
CL2018000007A1 (es) Compuestos inhibidores de la señalización de la vía de notch
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.